Early post-infarction pericarditis

Article written and reviewed by Dr Luca Moretti

Early post-infarction pericarditis, historically termed epistenocardiac pericarditis, is inflammation of the pericardium that typically occurs one to three days after myocardial necrosis, especially when the infarction reaches the epicardial surface. Inflammation extends directly from injured tissue to the visceral layer and adjacent pericardial space. Inflammatory contiguity distinguishes this form from the delayed immune syndrome. Early reperfusion has markedly reduced its frequency.
The classic presentation includes new pleuritic or positional chest pain and a pericardial friction rub during the hospital phase of infarction; however, ischemic, pericardial, and procedural pain may overlap, while the ECG is already altered by necrosis and does not always show the diffuse pattern of idiopathic pericarditis. The urgent differential diagnosis must exclude reocclusion, reinfarction, and mechanical complications. The quality of pain alone is insufficient.

A small effusion may accompany inflammation and remain stable. A new or enlarging effusion with hypotension, tachycardia, or signs of tamponade instead has a different significance because after infarction it may reflect hemopericardium due to free-wall rupture; a post-infarction effusion must not be trivialized. Serial echocardiography and hemodynamic assessment establish urgency and diagnosis.
Most early forms are transient and resolve with supportive therapy. The 2025 ACS guidelines reserve high-dose aspirin for persistent symptoms and consider colchicine to reduce symptoms and recurrence, avoiding automatic treatment of an asymptomatic effusion; therapeutic proportionality is particularly important after infarction. NSAIDs other than aspirin and glucocorticoids may interfere with healing and are avoided when possible.

The diagnosis also has indirect prognostic significance because it suggests necrosis extensive enough to reach the epicardial aspect. The patient must therefore be evaluated not only for pain but also for ventricular function, remodeling, arrhythmias, and other complications of a large infarction; the myocardial context remains decisive for outcome. Resolution of pericarditis does not automatically transform a patient with severe ventricular dysfunction into a low-risk patient.
Decisions also occur during a phase in which the patient receives many essential treatments and may have renal failure, anemia, or instability. Every anti-inflammatory addition must therefore be justified by symptoms and expected benefit, not by the diagnostic label alone; the medication burden increases the risk of interactions and toxicity. Daily review permits early discontinuation of what is no longer necessary.

Etiology, risk factors, pathogenesis, and pathophysiology

Myocardial necrosis releases mediators and activates inflammatory cells in the infarcted territory. When injury extends to the subepicardium, the response involves the epicardium and overlying pericardial surface, producing a fibrin-rich exudate and friction between the layers; transmural necrosis is the traditional substrate. Not every STEMI is pathologically transmural, and not every extensive infarction develops pericarditis.
Reperfusion limits the size and depth of necrosis and explains its contemporary rarity. Late presentation, failure to restore flow, a large territory at risk, and poor resolution of ST-segment elevation increase the likelihood of subepicardial injury; timely reperfusion provides indirect prevention. There is no routine anti-inflammatory prophylaxis for all patients with infarction.

The friction rub arises from movement of inflamed surfaces and may be transient, occur in one, two, or three components, and change with posture and stethoscope pressure. Abundant fluid may separate the layers and make it disappear; a dynamic friction rub is specific but insensitive. Its absence during a single examination does not exclude the condition.
Pain results from irritation of the parietal pericardium, which is innervated by the phrenic nerve, and is modified by breathing and position. Radiation to the trapezius is suggestive, while relief on sitting and leaning forward is classic but not constant; pleuritic pain reflects somatic involvement. Exertional pressure or pain with autonomic symptoms instead requires close attention to ischemia.

Exudation into the pericardial space is generally modest because duration is short and the involved surface may be regional. Pressure, however, depends more on the rate of accumulation than on absolute volume; a rapidly accumulating collection is less well tolerated than a chronic one; pericardial compliance determines the hemodynamic effect. During the post-infarction phase, the presence of blood radically changes interpretation.
The systemic inflammatory response to infarction may already produce low-grade fever, leukocytosis, and increased C-reactive protein, making these findings nonspecific. A second increase, high or persistent fever requires exclusion of infection, thrombosis, pneumonia, and other complications; inflammatory markers support activity but do not identify the etiology. Their trajectory is more useful than a single value.

The early form does not require the latency needed for an autoimmune response. Autoantibodies and the mechanisms of post-cardiac injury syndrome belong mainly to Dressler syndrome, which emerges weeks later and may involve the pleurae and lungs; pathogenetic separation avoids merging two temporally distinct conditions. Intermediate presentations nevertheless exist and require clinical judgment.
Anticoagulants and antiplatelet agents do not cause pericarditis, but they influence the risk and severity of pericardial bleeding if a mechanical lesion exists. Their management cannot be automatic because discontinuation increases coronary and stent thrombosis; the antithrombotic balance depends on the effusion, stability, and cause. Suspected hemopericardium requires an immediate multidisciplinary decision.

Coronary interventions may introduce a second mechanism of pericardial injury through perforation, intramyocardial hematoma, or microtrauma, but these conditions are not epistenocardiac pericarditis in the strict sense. The distinction changes urgency and antithrombotic management; a procedural injury should be sought when pain or an effusion temporally follows PCI. Review of the angiogram and fluid distribution helps separate the causes.

Pathological anatomy, classification, and evolution

The classic appearance is fibrinous pericarditis localized over the necrotic territory, with a dull surface and fibrin strands. In large infarctions, the reaction may become more extensive but remains anatomically linked to the recent myocardial lesion; epicardial fibrin explains auscultatory friction. Purulent exudate or a massive collection suggests different etiologies.
The term epistenocardiac describes the proximity of pericarditis to the infarcted area and acute phase. It is historically useful, but the designation early post-infarction pericarditis better communicates timing and clinical context; modern terminology does not change diagnostic criteria. It must, however, be distinguished from delayed immune pericarditis and postpericardiotomy pericarditis.

Temporally, typical onset is between the first and third days. Immediate onset during ischemic pain may be difficult to distinguish from infarction, whereas onset after weeks points toward Dressler syndrome or another cause; a short latency is a strong diagnostic feature. It is not an absolute limit if injury evolves or diagnosis is delayed.
The dry form presents with a friction rub without a significant effusion; the effusive form includes a generally small collection; this descriptive distinction alone does not establish severity because substantial pain may exist without fluid and an enlarging effusion may initially cause few symptoms; the effusive phenotype requires serial measurements. A loculated distribution after procedures may be missed through a single window.

The usual course is resolution within a few days with disappearance of pain and the friction rub. Fibrin is reabsorbed and a small effusion diminishes; clinically important adhesions and constriction are exceptional in the isolated form; the self-limited course supports proportionate treatment. Persistence beyond the expected phase requires reconsideration of the diagnosis.
Rapid progression of the collection, echodensity compatible with blood or clots, and signs of tamponade do not belong to a reassuring natural history. They should raise suspicion of free-wall rupture, procedural perforation, or another hemorrhagic source; hemorrhagic progression immediately changes the pathway. Imaging and surgical assessment are not delayed to await a response to anti-inflammatory drugs.

The ECG evolves concurrently with infarction and inflammation. Persistent ST-segment elevation may reflect an aneurysm or pericarditis, whereas new regional deviations may indicate ischemia; the diffuse pattern with PR-segment depression is less consistent than in idiopathic pericarditis. Electrocardiographic evolution must be compared with previous tracings. No single sign resolves all alternatives.
A recurrence after a symptom-free interval may represent recurrent pericarditis or the beginning of a delayed post-cardiac injury syndrome. Fever, pleural involvement, effusions, and systemic reactivation favor the latter; a late recurrence must be redefined etiologically. Mechanically repeating the same label may conceal reinfarction or infection.

Healing of the infarction replaces necrotic tissue with scar and progressively removes the contiguous stimulus; therefore, an early form that remains active for weeks does not follow the usual trajectory and requires MRI or further investigation for persistent inflammation, an organized effusion, or another etiology. Persistence beyond the acute phase is a diagnostic signal. It must not be treated indefinitely on the basis of the initial hypothesis without renewed verification.
The effusion may be free-flowing or, after procedures or previous adhesions, unevenly distributed. A posterior or loculated collection may not produce classic signs and requires complete scanning, while echogenicity and strands suggest fibrin or blood without independently identifying the cause; pericardial distribution modifies the sensitivity of standard windows. The description should include location, maximum thickness, respiratory variation, and temporal comparison.

Signs and symptoms

Pain is acute, sharp, or burning, worsens with deep inspiration, coughing, and recumbency, and often improves when sitting forward. It may overlap with residual pain from infarction and understandably raise concern about a new occlusion; the positional component increases the likelihood of a pericardial origin. Response to analgesics is not a diagnostic test and does not justify delaying an ECG.
The friction rub is a superficial, scratching sound, sometimes more evident at the lower sternal border with the patient leaning forward and during expiration. It may appear and disappear within hours, so auscultation should be repeated; the auscultatory finding has high specificity in the appropriate context. A new systolic murmur instead points toward a mechanical complication.

Low-grade fever and malaise may accompany the condition, but fever above 38 degrees, chills, hypotension, or marked leukocytosis must not automatically be attributed to pericarditis. Catheter-associated infection, pneumonia, and complications of infarction are important alternatives; systemic signs require a proportionate assessment. Simple early pericarditis is generally brief and nontoxic.
Mild dyspnea may result from inspiratory pain, whereas severe dyspnea, orthopnea, and hypoxemia suggest heart failure, mitral regurgitation, septal defect, pulmonary embolism, or a hemodynamically significant effusion. The symptom must be linked to the dominant mechanism; disproportionate dyspnea is not typical of dry inflammation alone. Echocardiography and radiography clarify concomitant causes.

A small effusion produces no specific physical signs. Tamponade may cause tachycardia, low blood pressure, pulsus paradoxus, jugular venous distention, and muffled heart sounds, but the classic triad has low sensitivity and right ventricular infarction may mimic part of the presentation; signs of tamponade require urgent confirmation. Sudden deterioration after infarction should first raise suspicion of rupture.
New retrosternal pressure, sweating, nausea, instability, or regional ECG changes must maintain a high probability of ischemia. Pericarditis does not protect against stent thrombosis, extension of infarction, or complications of PCI; recurrent ischemic pain retains therapeutic priority. Coronary angiography is repeated when the presentation requires it.

Pleuritic pain may also result from pulmonary embolism, pleuritis, pneumonia, pneumothorax, or the chest wall. Tachycardia, hypoxemia, hemoptysis, and thromboembolic risk factors guide investigation without indiscriminately multiplying CT scans; the extracardiac diagnosis remains part of the assessment. D-dimer has poor specificity after infarction and procedures.
Anxiety and hypervigilance are common after infarction and may amplify pain perception, but they must not be invoked before organic causes have been excluded. A clear explanation reduces alarm and promotes rehabilitation; the psychological context is addressed after clinical safety. Any change in the symptom deserves renewed characterization.

The medication history helps recognize nonpericardial symptoms and treatment risks. Nitrates may have modified ischemic pain, opioids may mask its evolution, and anticoagulants increase the consequences of a hemorrhagic collection; no pharmacological response is pathognomonic; the response to medication does not replace ECG and imaging. Dose timing and its relationship to the symptom should be documented before treatment is changed.

Investigations and diagnosis

In the post-infarction setting, the 2025 ACS guidelines propose pleuritic pain associated with at least one of a friction rub, compatible ECG changes, or a new or enlarging effusion; this scheme is more specific than the generic two-of-four criterion used in unselected acute pericarditis; the post-infarction criteria recognize the difficulty posed by an already abnormal ECG. Diagnosis remains clinical and integrated.
Serial ECGs assess territory, ST-segment dynamics, PR-segment depression, T-wave inversions, and arrhythmias. Diffuse concave ST-segment elevation with PR-segment depression supports pericarditis, but infarction often produces regional abnormalities that obscure the pattern; comparison of tracings is more informative than an isolated ECG. New territorial changes require exclusion of ischemia.

Troponin is already elevated because of infarction and does not diagnose pericardial inflammation. A new increase may indicate extension or reinfarction but must be interpreted with the previous curve, symptoms, ECG, and revascularization; biomarker kinetics have contextual value. CK-MB may provide additional information about new necrosis in selected situations without replacing imaging.
C-reactive protein, ESR, and leukocytes document inflammation but are influenced by infarction. A return toward normal values may accompany the response and guide aspirin tapering, whereas an unexpected rise prompts a search for other causes; CRP monitoring is complementary. It is not necessary to await normalization before treating a suspected mechanical complication.

Echocardiography measures effusion at multiple sites, looks for chamber collapse, respiratory variation, and vena caval plethora, evaluates ventricular function, and identifies mitral regurgitation, septal defect, or contained rupture. A normal initial examination does not exclude dry pericarditis. Urgent echocardiography is primarily a safety tool. Repetition depends on symptoms and the course of the collection.

Features used to diagnose early pericarditis after infarction

• Consistent timing: onset predominantly one to three days after an extensive infarction.
• Pleuritic pain: a symptom modified by breathing or position and distinct from the previous ischemic pressure.
• Additional sign: a friction rub, compatible ECG changes, or a new or enlarging effusion.
• Ischemia excluded: serial tracings, the clinical course, and coronary angiography when indicated exclude reocclusion.
• Rupture excluded: effusion and hemodynamic stability immediately assessed by echocardiography.

Cardiac MRI may show pericardial edema and enhancement, in addition to quantifying infarction and myocardial involvement, and is useful in persistent or equivocal cases in stable patients. It is not used to delay coronary angiography or an urgent procedure; tissue characterization strengthens complex diagnoses. Gadolinium, rhythm, devices, and tolerance of recumbency affect feasibility.
Chest radiography is often normal with respect to the pericardium but identifies edema, pneumonia, and pleural effusion; the silhouette enlarges only with substantial collections. CT is reserved for suspected embolism, aortic disease, a procedural complication, or unresolved pericardial anatomy. Selective imaging answers precise questions. Multiple tests without priorities may delay the necessary treatment.

Coronary angiography does not diagnose pericarditis but becomes necessary when symptoms, ECG, or instability do not permit exclusion of a new occlusion. If the pain is clearly pleuritic, the patient stable, and tracings do not suggest ischemia, a new invasive examination may be unnecessary; the threshold for coronary angiography depends on ischemic probability. A reasoned decision avoids both dangerous delays and repeated procedures without benefit.
The diagnosis of myopericarditis is not useful when troponin already reflects documented coronary necrosis; the issue is whether additional nonischemic myocardial inflammation exists, a rare event requiring specific MRI features and context. Using overlapping labels without evidence creates confusion. Ischemic myocardial injury remains the principal explanation for troponin. MRI distinguishes a coronary from a nonischemic distribution when the question genuinely changes management.

Treatment and prognosis

A mild, transient form without significant effusion may be managed with observation, relative rest, and analgesia. The 2025 ACS guidelines indicate that acetaminophen may be used for symptomatic relief and that many cases resolve with conservative treatment; supportive treatment avoids unnecessary exposure. The patient nevertheless remains monitored for ischemia and complications.
If pain persists, high-dose aspirin is the preferred anti-inflammatory agent after infarction. A suggested regimen is 500–1000 mg every six to eight hours until improvement, followed by gradual tapering guided by symptoms, tolerance, and inflammation. Anti-inflammatory aspirin exceeds the antiplatelet dose. Gastrointestinal risk, renal function, hemoglobin, and interactions must be evaluated.

Colchicine, 0.5–0.6 mg once or twice daily for approximately three months, may be considered for persistent symptoms or to reduce recurrence, with dose adjustment below 70 kg, in severe renal or hepatic dysfunction, and with P-glycoprotein or CYP3A4 inhibitors; adjunctive colchicine does not require a loading dose in this setting. Diarrhea and neuromuscular toxicity require surveillance.
Aspirin and colchicine are not routinely indicated for a small asymptomatic effusion. Treatment addresses clinically active inflammation, not the mere presence of a few millimeters of fluid; an enlarging collection instead requires etiological diagnosis; an asymptomatic effusion is monitored. Suppressing its signal with medication does not eliminate a possible hemorrhagic source.

Nonaspirin NSAIDs and glucocorticoids are avoided when possible after infarction because of associations with adverse healing, scar expansion, rupture, or a new event, in addition to renal and bleeding risks. An exception requires a strong indication and specialist assessment; the choice of anti-inflammatory agent is context-specific. Rules for idiopathic pericarditis cannot be transferred without adaptation.
Gastroprotection accompanies high-dose aspirin in appropriate patients. Creatinine, transaminases, complete blood count, and signs of bleeding are monitored, taking into account antiplatelet agents and any anticoagulant for ventricular thrombus or atrial fibrillation; medication safety requires review of the entire prescription. An anti-inflammatory dose must not be accidentally duplicated with over-the-counter products.

Intense physical activity is suspended during pain and inflammation and gradually resumed within the rehabilitation program after clinical resolution, infarct stability, and functional assessment. Restrictions for pericarditis must be integrated with those for the recent coronary event; return to activity does not follow an isolated number of days. Fever, symptoms, ECG, function, and complications determine the pathway.
The prognosis of the isolated form is favorable, and the condition generally resolves within a few days. Mortality does not usually result from inflammation but from infarct size or serious alternative diagnoses; its prognostic significance is therefore also as a marker of extensive necrosis. Persistence, recurrence, or a large effusion requires renewed assessment.

Before discharge, clinicians verify that pain and fever have resolved, that the effusion is not enlarging, and that the patient understands medication doses and tapering. Early follow-up is scheduled if an effusion or anti-inflammatory treatment persists and coordinated with the post-infarction cardiology visit; the follow-up plan prevents abrupt discontinuation and unnecessarily prolonged treatment. A relapse should be assessed, not managed solely by telephone.
Aspirin tapering occurs only after stable clinical improvement and is slowed if pain or CRP rises again, avoiding repeated oscillation between the minimum and maximum dose. Colchicine, when used, generally does not require gradual tapering but should be discontinued or adjusted in the event of toxicity; treatment tapering is guided by remission. The antiplatelet dose required after the anti-inflammatory phase is maintained according to the coronary indication.

Complications

Effusion is the most frequent complication but usually remains small. Rapid enlargement, echogenic blood or clots, chamber collapse, and deterioration require suspicion of free-wall rupture, not merely intensification of anti-inflammatory treatment; an enlarging effusion is a warning sign. Timely echocardiography may determine survival.
Tamponade due to early pericarditis alone is rare. After infarction, tamponade should be considered hemorrhagic or mechanical until proven otherwise, including coronary perforation and antithrombotic therapy as context; post-infarction tamponade requires a surgical and interventional team. Pericardiocentesis may stabilize the patient but does not repair a rupture.

A diagnostic error may delay treatment of coronary reocclusion. Pain attributed to pericarditis without serial ECGs or perfusion assessment may lead to a new infarction, whereas unnecessary coronary angiography exposes the patient to contrast and complications; misclassification of pain has consequences in both directions. The threshold for reassessing ischemia remains low.
High-dose aspirin combined with dual antiplatelet therapy or anticoagulation increases gastrointestinal and systemic bleeding. Renal failure, anemia, and interactions may complicate treatment, while colchicine causes gastrointestinal disturbances and, rarely, hematological or muscular toxicity; drug-related iatrogenesis is prevented by using the minimum effective duration. Every drug is reassessed when symptoms resolve.

A recurrence may follow overly rapid tapering of the anti-inflammatory drug or represent Dressler syndrome. The new episode requires confirmation of inflammation and reassessment for ischemia, pulmonary embolism, and infection, not simply autonomous resumption of treatment; reappearance of pain reopens the differential diagnosis. CRP and imaging help distinguish activity from residual pain.
Constrictive pericarditis after an uncomplicated early form is exceptional. Persistent signs of right-sided congestion, respiratory variation, and pericardial thickening months later instead suggest a more extensive, recurrent process or an alternative cause; late constriction is not diagnosed from the history alone. Echocardiography, CT, and MRI define physiology and anatomy.

Reduced activity due to fear may delay rehabilitation, whereas resuming too rapidly during inflammation may rekindle symptoms. Personalized guidance and a supervised pathway avoid both extremes; preventable disability is an underestimated consequence. Recovery must simultaneously respect the infarction, ventricular function, and pericardial remission.
Finally, the label of pericarditis must not obscure the entire post-infarction course: arrhythmias, heart failure, ventricular thrombus, and mechanical complications retain their respective risks. Follow-up verifies secondary prevention therapy and recovery in addition to disappearance of pain; post-infarction care remains comprehensive. Resolution of pericarditis is only one of the clinical objectives.

Another risk is fragmentation of care: intensive care, the catheterization laboratory, and the outpatient clinic may assign different meanings to the same effusion if comparable measurements and images are unavailable. The discharge summary should report onset, maximum thickness, course, medications, and excluded differential diagnoses; documentary continuity reduces subsequent errors. It permits a true recurrence to be distinguished from a previously known, stable residual collection.